BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma.

CONCLUSION: Overall, these data highlight the importance of mutational screening to better understand newly diagnosed MM (NDMM) and may lead to patient specific mutation-driven treatment approaches.
PMID: 31988198 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 26, 2020 Category: Cancer & Oncology Authors: Boyle EM, Ashby C, Tytarenko R, Deshpande S, Wang Y, Sawyer J, Tian E, Johnson S, Rutherford MW, Wardell CP, Bauer MA, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Wang H, Rosenthal A, Hoering A, Flynt E, Thakurta A, Dumontet C, Facon T, Cairns DA, Tags: Clin Cancer Res Source Type: research